The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | AMG 701 shows promise in heavily pre-treated myeloma patients
Simon Harrison, MBBS, MRCP (UK), PhD, FRCPath (UK), FRACP, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, discusses a Phase I first-in-human study (NCT03287908) evaluating the efficacy and safety of AMG 701, a BCMA-targeting half-life extended bispecific T-cell engager (BiTE), in relapsed/refractory (R/R) multiple myeloma. The study started with micro-dosing and proceeded with dose-escalation until adverse events emerged. High response rates were observed in the study cohort, particularly at higher dose levels. The recruitment for this study is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
